SCHEMBL4482477

SCHEMBL4482477

Cc1ccc(Cl)c(-c2ccc(CN3CCN(C(C)C)C(c4ccccc4)C3)cc2)c1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.63
MAPK1 P28482 2/20 0.41
LMNA P02545 2/20 0.40
POLB P06746 2/20 0.40
ALDH1A1 P00352 2/20 0.39
SIGMAR1 Q99720 1/20 0.38
PKM P14618 1/20 0.38
S1PR1 P21453 1/20 0.37
S1PR5 Q9H228 1/20 0.37
KDM4E B2RXH2 1/20 0.37
BCHE P06276 1/20 0.36
ACHE P22303 1/20 0.36
BACE1 P56817 1/20 0.36
PDE2A O00408 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4476472 0.88 CNR2 (0.57) CNR2MAPK1LMNAPOLBALDH1A1
SCHEMBL4472224 0.86 CNR2 (0.66) CNR2LMNAPOLBALDH1A1SIGMAR1
SCHEMBL4651291 0.86 CNR2 (0.56) CNR2MAPK1LMNAPOLBSIGMAR1
SCHEMBL4477059 0.85 CNR2 (0.56) CNR2MAPK1LMNAPOLBALDH1A1
SCHEMBL4477428 0.84 CNR2 (0.64) CNR2LMNAPOLBALDH1A1SIGMAR1
SCHEMBL14495607 0.84 CNR2 (0.63) CNR2LMNAPOLBALDH1A1SIGMAR1
SCHEMBL4472734 0.82 CNR2 (0.59) CNR2ALDH1A1S1PR1S1PR5KDM4E
SCHEMBL4481910 0.82 CNR2 (0.61) CNR2ALDH1A1S1PR1S1PR5KDM4E
SCHEMBL4466232 0.82 CNR2 (0.61) CNR2LMNAPOLBALDH1A1PKM
SCHEMBL4474465 0.81 CNR2 (0.60) CNR2LMNAPOLBALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CNR2 2/4885MAPK1 893/4885LMNA 3602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.